
|Articles|June 6, 2018
What every urologist needs to know about SpaceOAR® hydrogel
Advertisement
Study data has shown that SpaceOAR® hydrogel significantly improves quality of life for patients with prostate cancer who have undergone radiotherapy. But what does it take to implement this procedure into routine practice, and what can urologists expect regarding reimbursement?
In this supplement, practicing urologists will share perspectives on this procedure, addressing topics that include:
Advertorial Supported by:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
4
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
5











